← The Wire·Breaking·Consumer·

Apollo Global in talks to acquire J&J orthopedics unit, terms undisclosed

Apollo Global is in talks to acquire Johnson & Johnson’s orthopedics unit, Bloomberg News reports. The potential deal would test Apollo’s ability to deploy capital into a healthcare asset while adding transaction and execution risk before terms are known.

STOCK PHOTO · MAURÍCIO MASCARO

The story

Apollo Global is in talks to acquire an orthopedics unit from Johnson & Johnson. The talks follow J&J's broader effort to focus its portfolio, but it remains unclear whether the discussions are exclusive or advanced. No signed agreement or commitment to transact has been announced, so the situation remains subject to negotiations and potential approval requirements.

For Apollo Global, the direct mechanism is capital deployment into a healthcare business that could generate future fee or investment income, depending on the transaction structure. For J&J, a sale would potentially simplify the portfolio and provide proceeds, but details on how the unit contributes to current revenue or earnings are limited.

Key uncertainties include the purchase price, financing structure, valuation, expected closing date and the specific assets included in the unit. Apollo's FY2025 revenue was $32.0B, up 22.7% year over year, with a 10.6% net margin and $5.54 diluted EPS; those figures provide scale but do not quantify the effect of this potential acquisition.

The next useful milestones are confirmation of a signed agreement, disclosure of the assets and price, and Apollo's next earnings update for any effect on deployment, financing or fee-related earnings. J&J's comments on proceeds and portfolio strategy would also clarify the seller's rationale.

Our read · Fri, Sep 11

APO faces a mixed setup: the J&J orthopedics talks could add a new healthcare deployment opportunity, but absent terms the transaction and execution risks remain unpriced.

Why. The implication for APO turns on deal quality rather than the headline alone: a signed transaction at attractive terms could expand capital deployment, while an expensive or heavily financed purchase could dilute the benefit. With no price, structure, assets or closing timetable reported, the evidence does not support a directional equity call.

Both cases

The case it holdsApollo’s FY2025 revenue rose 22.7% to $32.0B, and acquiring a healthcare asset could extend its capital-deployment pipeline if the terms are favorable.
The case it breaksThe potential transaction's earnings impact remains entirely unestablished without details on valuation and financing terms.

What could change this view: The talks could end without a transaction, or disclosed terms could show an unattractive price, financing burden or limited earnings contribution.

Apollo Global Management stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

More on APO

Hackers breach Apollo Global as alternative-asset manager's AUM hits $1 trillion

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Investing.com as Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →